Sunway Healthcare Holdings Berhad (KLSE:SUNMED)
Malaysia flag Malaysia · Delayed Price · Currency is MYR
1.780
+0.030 (1.71%)
At close: Jun 10, 2026

KLSE:SUNMED Statistics

Total Valuation

KLSE:SUNMED has a market cap or net worth of MYR 20.47 billion. The enterprise value is 20.87 billion.

Market Cap20.47B
Enterprise Value 20.87B

Important Dates

The last earnings date was Wednesday, May 20, 2026.

Earnings Date May 20, 2026
Ex-Dividend Date n/a

Share Statistics

KLSE:SUNMED has 11.50 billion shares outstanding. The number of shares has increased by 5.27% in one year.

Current Share Class 11.50B
Shares Outstanding 11.50B
Shares Change (YoY) +5.27%
Shares Change (QoQ) +0.02%
Owned by Insiders (%) 0.11%
Owned by Institutions (%) 6.85%
Float 2.51B

Valuation Ratios

The trailing PE ratio is 83.18 and the forward PE ratio is 57.61. KLSE:SUNMED's PEG ratio is 2.76.

PE Ratio 83.18
Forward PE 57.61
PS Ratio 8.85
PB Ratio 6.26
P/TBV Ratio 6.33
P/FCF Ratio 727.60
P/OCF Ratio 44.64
PEG Ratio 2.76
Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 41.37, with an EV/FCF ratio of 741.70.

EV / Earnings 84.55
EV / Sales 9.02
EV / EBITDA 41.37
EV / EBIT 69.20
EV / FCF 741.70

Financial Position

The company has a current ratio of 1.93, with a Debt / Equity ratio of 0.49.

Current Ratio 1.93
Quick Ratio 1.81
Debt / Equity 0.49
Debt / EBITDA 3.20
Debt / FCF 57.44
Interest Coverage 4.67

Financial Efficiency

Return on Equity (ROE) n/a
Return on Assets (ROA) n/a
Return on Invested Capital (ROIC) 7.61%
Return on Capital Employed (ROCE) 6.48%
Weighted Average Cost of Capital (WACC) n/a
Revenue Per Employee n/a
Profits Per Employee n/a
Employee Count n/a
Asset Turnover n/a
Inventory Turnover n/a

Taxes

In the past 12 months, KLSE:SUNMED has paid 24.36 million in taxes.

Income Tax 24.36M
Effective Tax Rate 8.98%

Stock Price Statistics

Beta (5Y) n/a
52-Week Price Change n/a
50-Day Moving Average 1.88
200-Day Moving Average n/a
Relative Strength Index (RSI) 47.86
Average Volume (20 Days) 19,816,985

Short Selling Information

Short Interest n/a
Short Previous Month n/a
Short % of Shares Out n/a
Short % of Float n/a
Short Ratio (days to cover) n/a

Income Statement

In the last 12 months, KLSE:SUNMED had revenue of MYR 2.31 billion and earned 246.79 million in profits. Earnings per share was 0.02.

Revenue2.31B
Gross Profit 1.44B
Operating Income 301.54M
Pretax Income 271.16M
Net Income 246.79M
EBITDA 494.17M
EBIT 301.54M
Earnings Per Share (EPS) 0.02
Full Income Statement

Balance Sheet

The company has 1.22 billion in cash and 1.62 billion in debt, with a net cash position of -396.56 million or -0.03 per share.

Cash & Cash Equivalents 1.22B
Total Debt 1.62B
Net Cash -396.56M
Net Cash Per Share -0.03
Equity (Book Value) 3.27B
Book Value Per Share 0.28
Working Capital 853.76M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 458.51 million and capital expenditures -430.38 million, giving a free cash flow of 28.13 million.

Operating Cash Flow 458.51M
Capital Expenditures -430.38M
Depreciation & Amortization 192.63M
Net Borrowing 841.03M
Free Cash Flow 28.13M
FCF Per Share 0.00
Full Cash Flow Statement

Margins

Gross margin is 62.24%, with operating and profit margins of 13.03% and 10.67%.

Gross Margin 62.24%
Operating Margin 13.03%
Pretax Margin 11.72%
Profit Margin 10.67%
EBITDA Margin 21.36%
EBIT Margin 13.03%
FCF Margin 1.22%

Dividends & Yields

KLSE:SUNMED does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio 294.88%
Buyback Yield -5.27%
Shareholder Yield -5.27%
Earnings Yield 1.21%
FCF Yield 0.14%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value n/a
Lynch Upside n/a
Graham Number
Graham Upside

Analyst Forecast

The average price target for KLSE:SUNMED is 1.85, which is 3.93% higher than the current price. The consensus rating is "Buy".

Price Target 1.85
Price Target Difference 3.93%
Analyst Consensus Buy
Analyst Count 11
Revenue Growth Forecast (3Y) 17.28%
EPS Growth Forecast (3Y) 22.16%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

Altman Z-Score n/a
Piotroski F-Score 5